Brickell Biotech Inc. Stock News

Initiated U.S. pivotal Phase 3 clinical program (Cardigan I and II studies) evaluating sofpironium bromide gel, 15% for the treatment of primary axillary (underarm) hyperhidrosis

Webinar taking place on Friday, March 26th @ 10 am EDT Webinar taking place on Friday, March 26th @ 10 am EDT

Brickell (BBI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

T opline results from the U.S. pivotal Phase 3 program anticipated in the fourth quarter of 2021 Sofpironium bromide gel, 5% (ECCLOCK ® ) recently launched in Japan by development partner, Kaken Phar

Kaken plans to launch ECCLOCK ® for the treatment of primary axillary hyperhidrosis in Japan on November 26, 2020 - - - ECCLOCK ® placed on Japan's National Health Insurance (NHI) drug reimbursement

BOULDER, Colo., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated pre

Brickell Biotech, Inc. (BBI) CEO Robert Brown on Q3 2020 Results - Earnings Call Transcript

Recently completed capital raise expected to fully fund U.S. pivotal Phase 3 program, with topline results anticipated in Q4 2021 - - - Initiated the Cardigan I study, the first of two U.S. pivotal Ph

BOULDER, Colo., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated pre

The

The following slide deck was published by Brickell Biotech, Inc. in conjunction with this event..

Brickell Biotech, Inc. (NASDAQ:BBI) Q2 2020 Results Earnings Conference Call August 12, 2020, 04:30 PM ET Company Participants Daniel Ferry - Investor Relations, LifeSci Advisors Robert Brown - Chief

Positive data from the Sofpironium Bromide Phase 3 pivotal study in Japan presented in Q2 2020 by development partner, Kaken Kaken to receive regulatory decision in Japan for sofpironium bromide g

Biotech stocks advanced in the week ended Aug. 7, buoyed by multiple catalysts. Aside from the broader market strength, mostly positive earnings and continuing coronavirus...